GlassScriptPhysician profile
Ramakrishna V Chava
NPI 1790998706
$2,361.22
in general payments reported to CMS, 2019-2025
33 companies · $87.76 in 2025
The $87.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $95.10 · 2021: $293 · 2022: $562 · 2023: $446 · 2024: $132 · 2025: $87.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $290.83 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $266.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $197.26 | 2019-2023 | |
| Lilly USA, LLC | $179.74 | 2019-2023 | Trulicity, Amyvid, Humalog |
| Sunovion Pharmaceuticals INC. | $132.08 | 2019-2021 | |
| Pfizer INC. | $131.34 | 2019-2021 | |
| Abbott Laboratories | $127.96 | 2022-2023 | Prodigy, Proclaim, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $120.60 | 2021-2024 | Xarelto |
| Aquestive Therapeutics, INC. | $117.38 | 2022 | |
| Sumitomo Pharma America, INC. | $88.00 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $74.25 | 2023-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $59.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $53.87 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.65 | 2021-2025 | Xifaxan, Trulance |
| Abiomed | $44.80 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35.00 | 2021-2024 | |
| Smith+Nephew, INC. | $34.86 | 2024 | Collagenase Santyl |
| Eisai INC. | $34.43 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $32.97 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $32.97 | 2019-2020 | |
| Philips North America LLC | $27.32 | 2022-2024 | (Ak6) Vest Therapy |
| Mannkind Corporation | $25.95 | 2020 | |
| Ucb, INC. | $24.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.58 | 2019-2020 | |
| Kyowa Kirin, INC. | $23.37 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.67 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $18.29 | 2019 | |
| Dexcom, INC. | $17.83 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $16.53 | 2023 | |
| Recor Medical INC | $16.38 | 2024 | Paradise Renal Denervation System |
| Idorsia Pharmaceuticals US INC | $16.19 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $15.53 | 2022 | |
| Mylan Specialty L.P. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramakrishna Chava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.